Table 1.
Phytochemicals | Approaches | Action mechanisms | Major outcomes | References |
---|---|---|---|---|
Curcumin | Gastrointestinal health | BiP ↓ and IL-8 ↓, in IECs | Anti-inflammation ↑ and ER stress ↓ | [27, 28, 29, 30, 31] |
Serotonin ↓, BDNF ↓, and pCREB ↓, in gut | Gut function ↑ | |||
Mesenteric afferent nerve response by colorectal distension or capsaicin ↓ | Gut nociception ↓ | |||
NO ↓, lipid peroxides ↓, neutrophils infiltration ↓, and cell apoptosis ↓, in TNF-α-colitis | Antioxidation ↑ | |||
Naïve CD4(+) T cells differentiation ↑, Treg ↑, and IL-10-producing Tr1 cells ↑, in intestine | Intestinal lamina propria immunity ↑ | |||
Systemic immunity | Circulating IL-6 ↓, DC maturation ↓, proinflammatory cytokine ↓, and allospecific T cell response ↓ | Systemic inflammation ↓ | [51, 52, 53, 54, 55, 56] | |
Monocyte phagocytosis of Aβ ↑ and TLRs 2–4 ↑, in AD | Systemic immunity ↑ | |||
IL-6 ↓, TNF-α ↓, IFN-γ ↓, IL-17 ↓, Cox-2↓, IL-10 ↑, and Treg cells ↑, in lymphoid organs or macrophages. | Anti-inflammation ↑ and innate immunity ↑ | |||
Neuroimmunity | Glial activation ↓, NF-κB↓, TNF-α ↓, IL-1β ↓, IL-1α ↓, IL-6 ↓; inducible NOS ↓, Cox-2 ↓; Bax↓, Bcl-2 ↓, caspase 3↓, and caspase 9↓, in AD and PD models | Anti-inflammation ↑, antioxidation ↑, and antiapoptosis ↑ | [10, 77, 78, 79, 80] | |
Tau aggregation ↓ and neurotoxicity ↓, in neurons | Neuroprotective effect ↑ | |||
| ||||
Resveratrol | Gastrointestinal health | Occludin ↑ and zonula occluden (ZO-1) ↑, in IECs | Intestinal mucus integrity ↑ | [32, 33, 34] |
ROS accumulation ↓, SOD ↑, and HO-1 ↑ | Antioxidation ↑ | |||
T helper cells ↓, Treg cells ↑, and IEC proliferation ↑, in ileitis | Gut barrier function ↑ and microbiota dysbiosis ↓ | |||
Lactobacilli ↑, bifidobacteria ↑, and enterobacteria ↓ | Colonic mucosa architecture ↑ | |||
PGE-2 ↓, Cox-2 ↓, PGE synthase ↓, and NO ↓, in colonic mucosa | Antioxidation ↑ and anti-inflammation ↑ | |||
Systemic immunity | Cytokines (TNF-α, IL-1α, IL-1β, IFN-γ, IL-6, IL-8, and IL-10) ↓, chemokines (C-C motif ligand 2 (CCL2), CCL5) ↓, ROS ↓, Cox-2 ↓, PGE-2 ↓, ICAM-1 ↓, and CSFs ↓, in monocytes and macrophage | Antioxidation ↑ and anti-inflammation ↑ | [58, 59, 60] | |
Neuroimmunity | Glial activation ↓, NF-κB ↓, and cytotoxic factors (TNF-α, NO, IL-1β, IL-6, and C-reactive protein) ↓ | Neuroprotective effect ↑, on cortical neurons | [11, 81, 84, 85, 86] | |
Lymphocyte infiltration ↓, protein IL-17A ↓, matrix metalloproteinases, ↓, and tight junction proteins ↑, in BBB-disrupted mice | BBB integrity ↑ | |||
| ||||
Propolis (flavonoids, CAPE, or chrysin) | Gastrointestinal health | Occludin ↑, ZO-1 ↑ and colon fibrosis ↓, in IECs | Epithelial barrier function ↑ | [35, 36, 37, 38] |
NF-κB↓, proinflammatory cytokines ↓, and IP-10 ↓ | Antioxidation ↑ and anti-inflammation ↑ | |||
Systemic immunity | Phagocytosis↑ and cytotoxicity (IL-1β, IL-6, TLR-2, and TLR-4) ↑, in peritoneal macrophages | Cellular immunity ↑ | [62, 64, 65, 66, 67, 68] | |
Circulating proinflammatory cytokines (TNF-α, IL-1α, IL-1β, IL-6, IL-4, and ICAM-1) ↓ and anti-inflammatory cytokines (IL-10) ↑, in LPS-induced systemic inflammation | Systemic inflammation ↓ | |||
NO ↓, MAPK ↓, and NF-κB ↓, in mast cells and macrophages | Antioxidation ↑ and anti-inflammation ↑ | |||
Neuroimmunity | NF-κB ↓, TNF-α ↓, IL-1β ↓, IL-6 ↓, NOS ↓, NO ↓, ROS ↓, Cox-2 ↓, and caspase-3 ↓, in microglia or PD mice | Antioxidation ↑, and anti-inflammation ↑, for neurons | [12, 61, 87, 88, 89, 90, 91] | |
| ||||
PUFAs (ω-3 PUFAs) | Gastrointestinal health | NF-κB ↓, Cox-2 ↓, PGE-2 ↓, and leukotriene B4 ↓ | Anti-inflammation ↑, in gut | [39, 40, 41, 42, 43] |
TRPA1 activation ↑ | Gastrointestinal function ↑ | |||
Intestinal mucosa permeability ↓, gut microbiota ↑, IL-15 ↓, TNF-α ↓, IFN-γ ↓, IL-4 ↓, and IL-10 ↓ | Gut immune barrier function ↑ | |||
Systemic immunity | IL-17 ↓, IL-6 ↓, IL-23 ↓, and Treg cells ↑, in spleen | Anti-inflammation ↑ and immune function ↑ | [69, 70, 71] | |
Neuroimmunity | Glial activation ↓, ω-3/ω-6 PUFA balance ↑, amyloid precursor protein (APP) ↓, NF-κB ↓, IL-6 ↓, TNF-α ↓, BDNF, and its receptor ↑ | Neuroprotection ↑, anti-inflammation ↑, and brain innate immunity ↑ | [93, 94, 95, 96, 97, 98] | |
| ||||
Ginsenosides (Rb1, Rb2, Rg3, Rh2, Rh3, Rg1, Rg2, and Rh1) | Gastrointestinal health | TNF-α ↓, IL-1β ↓, IL-6 ↓, IL-17 ↓, IL-10 ↓, CREB ↑, glucose transporter 1 ↑, and gut contractility ↑ | Anti-inflammation ↑ and gastrointestinal function ↑ | [45, 46, 47, 48] |
Systemic immunity | NF-κB ↓, TNF-α ↓, IL-1β ↓, and PI3K/Akt/mTOR pathways ↑ | Anti-inflammation ↑ and enteric nutrition ↑ | [45, 48, 72, 73, 74] | |
Phagocytic uptake ↑ and ROS generation ↑ | Innate immunity ↑ | |||
Neuroimmunity | Glial activation ↓, ROSs ↓, TNF-α ↓, and IL-6 ↓, in the hippocampus | Anti-inflammation ↑ and antioxidation ↑ | [100, 101, 102, 103, 104] | |
CD14 ↓, NO ↓, TNF-α ↓, IL-6 ↓, IL-1β ↓, Cox-2 ↓, and inducible NOS ↓, in microglia |
Notes: ↑: increased; ↓: decreased; IECs: intestine epithelial cells; abbreviations are shown in the text.